Total: $759.14

Company
(Symbol)#
(M)

Type Of
Financing

Number Of
Shares, Units
Or Warrants

Amount
Raised
(M)

Investors; Placement Agents; Details
(Date)@


AEterna
Zentaris Inc.
(Canada; AEZS)

Sale of stock in subsidiary

3.485S

C$55.1 ($48.4)

AEterna sold nearly 3.5M shares of subsidiary Atrium Biotechnologies Inc. at C$15.80 each; AEterna now has about 11M Atrium shares, a stake of about 36.1% (10/18)

Accentia Bio-
pharmaceuticals
Inc.
(ABPI)

Convertible debenture financing

N/A

$25

The four-year, 8% debenture provides for the conversion into stock at $2.60 per share; warrants representing 35% of the stock are convertible into shares at $2.75 each; Rodman & Renshaw LLC was placement agent (10/2)

Acorda
Therapeutics
Inc.
(ACOR)

Private placement of stock

3.23S

$31.5

The shares were sold at $9.75 each to a limited number of accredited investors (10/4)

Amarin Corp. plc (UK; AMRN)

Registered direct offering

9S

$18.7

The registered shares were sold to new and existing investors at $2.09 each, a discount of 15% to the closing price of its ADSs on Oct. 18 (10/19)

Antigenics
Inc.
(AGEN)

Private placement of convertible notes

N/A

$25

The five-year, 8% notes are convertible into common stock at $3.50 per share; they also can be converted into a 30% interest in Antigenics' QS-21 and AG-707 programs (10/31)

Ariad
Pharmaceuticals
Inc.
(ARIA)

Private placement of stock

3.11S

$14.5

The shares were sold from a shelf registration at $4.65 in a deal underwritten by Credit Suisse Securities LLC, which has an option to purchase up to 466,942 additional shares to cover overallotments (10/20)

Biovitrum AB
(Sweden;
SSE:BVT)

Warrants exercise

0.623S

SEK36.8 ($5)

Investors exercised warrants to purchase about 0.623M shares (10/10 and 10/12)

Callisto
Pharmaceuticals
Inc.
(AMEX:KAL)

Private placement of convertible stock and warrants

0.105S and 1.4W

$1.05

The company sold 105,000 Series A convertible shares, and 1.4M five-year warrants exercisable at $0.75 per share (10/27)

Chromos
Molecular
Systems Inc.
(Canada; TSX:CHR)

Bridge loan

N/A

C$2 ($1.77)

The bridge loan was provided by a syndicate that included Pender NDI Life Sciences Inc., Pender Growth Fund Inc., NeuroDiscovery Ltd. Partnership and Rix Professional Medical Corp. (10/20)

CollaGenex
Pharmaceuticals
Inc.
(CGPI)

Credit facility

N/A

N/A

CollaGenex expanded its line of credit to $10M from $5M under a loan modification agreement with SVB Silicon Valley Bank; any borrowing would be at the prime rate (10/11)

Critical
Therapeutics
Inc.
(CRTX)

Private placement of stock and warrants

7.456S and 3.728W

$20

The securities were sold to institutional investors; the five-year warrants are exercisable at $2.62 per share; Lazard Capital Markets LLC was placement agent (10/27)

Encysive
Pharmaceuticals
Inc.
(ENCY)

Equity financing commitment

N/A

N/A

Azimuth Opportunity Ltd. committed to buy up to $75M of registered Encysive stock over 18 months, at a discount to the market price; Encysive will control the timing and amount of any sales (10/20)

Evolutec
Group plc
(UK; AIM:EVC)

Private placement of stock

2.359S

£2.8 ($5.3)

Existing investors purchased the stock at 118 pence per share (10/26)

Idera
Pharmaceuticals
Inc.
(AMEX:IDP)

Private placement of stock

0.781S

$4

Shares were sold at $5.12 to Biotech Shares Ltd. under an equity financing agreement they entered in March; Idera can draw down another $2.25M through 2006 (10/24)

Innate Pharma
SAS
(France;
Euronext:IPH)

Private placement of stock

1.1S

€5 ($6.4)

Novo Nordisk A/S invested €5M concurrent with Innate's initial public offering, increasing its stake in Innate to 20% from 18.4% (10/31)

Insert
Therapeutics
Inc.
(subsidiary
of Arrowhead
Research Corp.;
ARWR)

Private placement of stock and warrants

10S and 4W

$10

Units sold at $1 each consist of a share of Series C-2 preferred stock and 40% warrant coverage to purchase Series D preferred shares at $1.25 each; Arrowhead invested $5M in the deal, and owns 64.5% of Insert (10/26)

Iomai Corp.
(IOMI)

Private placement of stock

2.283S

$10

Essex Woodlands Health Ventures and New Enterprise Associates are purchasing the shares at $4.38 each (10/23)

Lev
Pharmaceuticals
Inc.
(OTC BB:LEVP)

Private placement of stock and warrants

32.3S and 9.69W

$21

Shares were sold at $0.65 each; the five-year warrants are exercisable at $0.84 per share; placement agent Rodman & Renshaw LLC got another 1.7M warrants as part of the deal, on the same terms (10/23)

Lexicon
Genetics
Inc.
(LEXG)

Private placement of stock

10.58S

$40

The shares are being sold at $3.78 each; Banc of America Securities LLC was lead placement agent; Lazard Capital Markets LLC was co-agent (10/23)

Memory
Pharmaceuticals
Corp.
(MEMY)

Private placement of stock and warrants

28.2S and 7.1W

$32.2

Great Point Partners, MPM Capital and other investors purchased the stock at $1.11 per share; the five-year warrants, purchased for $0.125 each, are exercisable at $1.33 per share (10/5)

Monogram
Biosciences
Inc.
(MGRM)

Credit line

N/A

N/A

Merrill Lynch Capital provided a line of credit of up to $10M; the agreement expires in March 2010 (10/3)

NeuroSearch
A/S
(Denmark;
CSE:NEUS)

Rights issue

3.97S

DKK397 ($68)

Shares were sold at DKK100 each in the rights offering; Danske Markets was underwriter for the deal (10/19)

Ondine
Biopharma
Corp.
(Canada;
TSX:OBP)

Bought-deal financing

6.25S

C$10
($8.9)

The shares were purchased by a syndicate led by Canaccord Capital Corp. and including Desjardins Securities Inc. and Pacific International Securities Inc.; they have an overallotment option to purchase up to 937, 500 additional shares (10/20)

Pharmacopeia
Drug Discovery
Inc.
(PCOP)

Private placement of stock and warrants

5.8S and 1.45W

$25

Shares were sold at the Oct. 12 closing price of $4.28 per share; the five-year warrants are exercisable at $5.14 per share; CIBC World Markets Corp. was lead underwriter; Merriman Curhan Ford & Co. was co-manager (10/13)

Phylogica Ltd.
(Australia;
ASX:PYC)

Private placement and share purchase plan

12.93S

A$3.75 ($2.8)

Shares were sold at A$0.29 each, a 20% discount to the five-day average; Cygnet Capital partially underwrote the deal (10/20)

Poniard
Pharmaceuticals
Inc.
(PARD)

Term loan

N/A

$15

SVB Silicon Valley Bank and Merrill Lynch Capital provided the 42-month loan (10/26)

Senesco
Technologies
Inc.
(AMEX:SNT)

Private placement of stock and warrants

1.986S and 0.993W

$2.3

About $1.5M of the investment was provided by certain company directors; the warrants are exercisable at 110% of the stock purchase price (10/11)

SIGA
Technologies
Inc.
(SIGA)

Private placement of stock and warrants

2S and 1W

$9.1

The shares are being sold at $4.54 each, and the seven-year warrants are exercisable at $4.99 per share; Empire Financial Group and The Shemano Group were placement agents (10/19)

Trubion
Pharmaceuticals
Inc.
(TRBN)

Private placement of stock

0.8S

$10.4

Wyeth purchased the shares at $13 each, concurrent with Trubion's initial public offering of shares at the same price (10/18)

United
Therapeutics
Corp.
(UTHR)

Private placement of convertible notes

N/A

$250

The 0.5% notes due in 2011 are convertible into a combination of stock and cash at an initial rate $75.2257 per share; totals include the purchase of a $40M investor overallotment option (10/25)

Vical Inc. (VICL)

Registered direct offering

4.98S

$25

An investment fund of Temasek Holdings Ltd. is purchasing the registered stock at $5.02 per share (10/19)

Vical Inc.
(VICL)

Registered direct offering

2.5S

$12.5

The shares were sold from a shelf registration at the Oct. 13 closing price of $5.02 per share; no discounts or commissions were paid (10/16)

VioQuest
Pharmaceuticals
Inc.
(OTC BB: VQPH)

Private placement of stock and warrants

7.9S and 2.8W

$3.95

The shares were sold at $0.50 each; the five-year warrants are exercisable at $0.73 per share; Paramount BioCapital Inc. was placement agent (10/24)

Viragen
International
Inc.
(OTC BB:VGNI)

Preferred stock sale

N/A

$0.77

The Series D preferred stock carries a dividend of 24% per year (10/6)

York Pharma
plc
(UK; AIM:YRK)

Private placement of stock

3.09S

£3 ($5.6)

The shares were sold to institutional investors at 97 pence each (10/13)


Notes:
This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt.
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
Currency conversions are based on exchange rates at the time of the deal.
N/A = Not applicable; ND = Not disclosed.
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange.

No Comments